Home > Insider Trading > Filing (0000950170-24-003076)

Filing Details

Accession Number:: 0000950170-24-003076
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-08 18:01:26
Reporting Period:: 2024-01-05

Accepted Time:: 2024-01-08 18:01:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1937653	Zymeworks Inc.	ZYME	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1938192	Andrew Paul Moore	C/O Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-01-05	17,166	$0.00	17,166	No	4	M	Direct
Common Stock	Disposition	2024-01-05	7,460	$10.65	9,706	No	4	S	Direct
Common Stock	Disposition	2024-01-08	2,339	$11.22	7,367	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2024-01-05	17,166	$0.00	17,166	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-01-05	90,000	$0.00	90,000	$10.56
Common Stock	Restricted Stock Unit	Acquisiton	2024-01-05	60,000	$0.00	60,000	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
34,334		No	4	M	Direct
90,000	2034-01-04	No	4	A	Direct
60,000		No	4	A	Direct

Footnotes

Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
The RSUs vest in three equal annual installments beginning on January 5, 2025.